ArticleOncotarget2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.European urology oncology · 2022Trial
- Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.The Lancet. Oncology · 2021Trial
- Trial
- Oligoprogressive renal cell carcinoma: What is the role of surgery?BJU international · 2026Review
- Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Impact of local therapy in metastatic renal cell carcinoma during medical treatment in a retrospective analysis.Scientific reports · 2025Article
- Outcomes of Radiotherapy in Oligoprogressive Breast Cancer.Journal of personalized medicine · 2024Article
- Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2024Review
- Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.Cancer research and treatment · 2024Article
- The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.Journal of thoracic disease · 2023Article
- Review
- Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives.Cancers · 2022Review
- Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2022Review
- Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.Drugs in R&D · 2021Article
- Diagnostic Accuracy and Prognostic Value of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Septic Patients outside the Intensive Care Unit.Medicina (Kaunas, Lithuania) · 2021Article
- Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review.Translational lung cancer research · 2021Review
- Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study.Advances in therapy · 2021Article
- Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer.Clinical medicine insights. Case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locoregional treatment with radical intent should be considered during therapy with targeted agents in patients with metastatic renal cell carcinoma (mRCC) in order to achieve a complete response, especially in the setting of an oligo-progression in one or more metastatic sites. We retrospectively enrolled 55 patients who experienced a disease oligo-progression after at least 6 months from the beginning of first-line therapy in one or more metastatic sites radically treated with locoregional treatments. Post-first-oligo-progression overall survival (PFOPOS) and post-first-oligo-progression free survival (PFOPFS) were evaluated. The global median PFOPOS and PFOPFS were 37 months and 14 months respectively. Patients who continued the same therapy after a locoregional treatment on a site of progression had a significantly longer mPFOPOS compared to patients who changed therapy (39
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.